

Remarks

Reconsideration of this Application is respectfully requested.

Upon entry of the foregoing amendment, claims 176-233 are pending in the application, with claims 176 and 209 as the independent claim. Claims 166-175 have been cancelled without prejudice to or disclaimer of the subject matter therein. New claims 176-233 have been added. The specification has been amended to cancel the priority claim. These changes are believed to introduce no new matter, and their entry is respectfully requested.

Examples of Support for New Claims 176 - 233

Support for the new claims may be found throughout the specification, as summarized below.

<u>Claim language</u>	<u>Specification</u>
p53 epitope	p. 24, line 20
8-11 amino acids	p. 3, lines 5-7 and 19-20
Pro at P2, L or I at C-term	p. 2, lines 19-23; p. 3, lines 2-7, 13-15, 19-20; p. 4, lines 21-23
Contacting & binding HLA	p. 5, lines 3-8; p. 11, lines 27-32
Endogenous processing	p. 11, lines 39-41 (see also support below for fusion proteins, vaccine administration, etc.)

15 amino acids	p. 3, lines 5-6
Fusion protein	p. 13, lines 26-27; p. 15, lines 26-30; p. 16, lines 16-22, and line 31 to p. 17, line 9, lines 22-23, and lines 28-33; p. 22, lines 10-18
T helper peptide	p. 15, lines 26-30; p. 16, lines 7-11
Spacer	p. 15, lines 30-33; p. 16, line 32 to p. 17, line 9
Homopolymer & Heteropolymer	p. 22, lines 10-15
Expression vector	p. 17, lines 16-23; p. 23, lines 6-18
Serve as CTL target	p. 5, lines 8-10
Induce CTL response	p. 3, lines 8-12; p. 5, lines 10-11
Elicit response in patient & in patient CTL precursors	p. 23, lines 6-28
Diagnosis, prognosis	p. 2, lines 32-33; p. 23, lines 29-33
Vaccine composition	p. 6, lines 5-7; p. 22, lines 8-32
Individual human, population	p. 6, lines 5-7; p. 18, lines 12-14; p. 19, lines 5-11
Particular epitopes	Table 5, p. 26

Other Matters

As requested by the Examiner, Applicants will shortly amend the specification to set forth SEQ ID NOS, submit a supplemental declaration to add the post office address of the second inventor, and submit another copy of the sequence listing in compliance with 37 C.F.R. §§ 1.821-1.825.

Prompt and favorable consideration of this Amendment is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Helene C. Carlson
Agent for Applicants
Registration No. 47,473

Date: 3/12/2002

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

P:\USERS\HCARLSON\2060\001\001-2\Prel Amend.wpd

SKGF Rev. 2/13/01

Version with markings to show changes made

In the Specification:

The paragraph beginning on page 1, line 8.

This application is related to [is a continuation-in-part of] application U.S. Serial No. 08/344,824 [08/344,842], filed November 23, 1994, and is related to [which is a continuation-in-part of] application U.S. Serial No. 08/278,634, filed July 21, 1994, both of which are incorporated herein by reference.

In the Claims:

Claims 166-175 have been canceled.

Claims 176-233 have been added.